Aardvark Therapeutics, Inc. (NASDAQ: AARD) reported a second-quarter loss per share of $(0.66), beating the analyst consensus estimate of $(0.91) by 27.47 percent. The San Diego-based clinical-stage biopharmaceutical company maintained a flat net loss trajectory at $14.4 million for the quarter ended June 30, 2026, identical to the same period in 2025. This earnings beat comes as the company navigates a clinical hold on its lead program, ARD-101, while managing liquidity with a cash position of $73.9 million.

The per-share improvement reflects adjustments in share count or accounting treatments that were not present in prior periods, allowing the company to outperform market expectations despite identical net loss figures. Analysts had projected a deeper loss of $(0.91) per share, making the actual result a notable deviation from consensus views. The company’s total assets stood at $81.5 million as of June 30, 2026, down from $117.2 million at the end of 2025, reflecting ongoing operational expenditures and reduced cash reserves from $91.2 million in the first quarter.

Financial Performance

Research and development (R&D) expenses declined to $10.5 million in Q2 2026, a decrease of $2.7 million or approximately 20% compared to $13.1 million in the prior-year period. This reduction was primarily driven by a $3.3 million drop in external expenses related to chemistry, manufacturing, and controls (CMC), clinical, and toxicology studies for ARD-101. The cost savings resulted from the termination of the Phase 3 HERO trial and the associated Open Label Extension (OLE) trial in June 2026, following a full clinical hold placed by the U.S. Food and Drug Administration (FDA) in May 2026.

General and administrative (G&A) expenses rose to $4.6 million from $2.7 million in the second quarter of 2025, an increase of $1.9 million. The rise included additional public company operating costs, higher personnel costs prior to a June workforce reduction, bonuses, and $0.5 million in severance expense. Total operating expenses for the quarter amounted to $15.1 million, compared to $15.8 million in Q2 2025. Other income, net, contributed $697,000, reducing the overall loss from operations of $15.1 million to the final net loss of $14.4 million.

What the Numbers Show

The divergence between the flat net loss and the significant EPS beat highlights the impact of capital structure changes or share count adjustments on per-share metrics. While external study costs dropped sharply due to trial terminations, the increase in G&A expenses—driven by public company compliance costs and severance—absorbed much of the potential savings. The stability in net loss despite a significant reduction in R&D spend underscores the structural cost pressures facing early-stage biotechs during clinical setbacks. The projected runway into late 2027 relies heavily on no further major capital expenditures beyond those already implemented.

Tien Lee, M.D., Founder and Chief Executive Officer, stated that the company remains in active discussions with the FDA to resolve the clinical hold. In the third quarter of 2026, Aardvark will assess the unblinded data from the HERO and OLE trials to determine the totality of efficacy and safety results, which will inform next steps for the ARD-101 program.

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Neutral rating for Aardvark Therapeutics, maintaining a price target of $6. The rating applies to the company's stock listed on NASDAQ under the ticker symbol AARD. The reiteration reflects the analyst's current stance on the stock's valuation and market performance.

Analyst Rating and Price Target

The brokerage firm's decision to keep the Neutral rating suggests that the stock is expected to perform in line with the broader market. The $6 price target provides a specific benchmark for investors to evaluate the stock's potential upside or downside.